Abstract 5010
Background
Although immunotherapy treatment (ImT) supposes a great advance for cancer patients, it also presents a challenge to health professionals, not only because of their adverse-event profile differs from chemotherapy or radiotherapy but, because it introduces new areas of clinical practice. All Immunotherapy Clinical Guidelines highlight the importance of prevent adverse effects related-IrAE, education and monitoring patients is crucial. In 2018 the Catalan Institute of Oncology (ICO), along with 4 European oncology institutions launched the VIKHI project, (Virtual International Knowledge Hub in Inmuno-Therapy) to improve care delivery, education of professionals and patients on receiving ImT through a comprehensive training program. Objective: cross-sectional study evaluating knowledge that patients have about their immunotherapy treatment.
Methods
From July 2018-March 2019, all patients treated with ImT first time were recruited non-probabilistic sample. They had to answer 10 questions about their knowledge on disease & treatment, and quality of life with EORTC-QLC30 scale. The interviews were conducted by clinical nurse specialist.
Results
A total of 85 patients. By tumors; lung 74.11%, head-neck 7.05%, melanoma 5.88%, renal 3.52% and double tumors 9.41%. They received ImT as part as their standard treatment in 62.35% and 37.64% as clinical trial and in 31.77% were their first treatment. 91.76% patients were knowledgeable about receiving ImT, but only 3.52% were not aware and 4.70% describe Chemo+ImT. About being able to identify complications, diarrhoea was the most described by 25.23%, followed by skin problems by 23.38%, thyroid problems and fever 13.53% and alopecia by 0.30%. Only two patients were unable to identify any. Informed by oncologist 63.5% and by nurses 32.9%. Only 7% of patients considered being fully informed.
Conclusions
Still room to improve about patient education and communication for patients receiving ImT. It would be important to train the HCP’s, especially nurses, so that they can effectively inform and educate patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Catalan Institute of Oncology.
Funding
Independent Educational Grant from Pfizer IGCL Grant ID: 34096003.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3809 - Differential expression of various miRNAs in Pediatric Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)
Presenter: Vikas Gaur
Session: Poster Display session 3
Resources:
Abstract
4750 - Circulating tumour cells in head and neck and non-small cell lung cancer
Presenter: Kenneth O'Byrne
Session: Poster Display session 3
Resources:
Abstract
3704 - OX40/OX40L protein expression in Non-small cell lung cancer and its role in clinical outcome and relationships with other immune biomarkers
Presenter: Xiaoshen Zhang
Session: Poster Display session 3
Resources:
Abstract
2235 - Effect of Serum Survivin on Survival among Non-Small Cell Lung Cancer Patients; NCI Experience
Presenter: Reham Rashed
Session: Poster Display session 3
Resources:
Abstract
2788 - Enhanced performance of prognostic estimation from TCGA RNAseq data using transfer learning.
Presenter: Helene Vanacker
Session: Poster Display session 3
Resources:
Abstract
4689 - Analysis of Circulating Tumor DNA for Early Relapse Detection in Stage III Colorectal Cancer After Adjuvant Chemotherapy
Presenter: Samuel Jacobs
Session: Poster Display session 3
Resources:
Abstract
1454 - Ascites-derived circulating microRNAs as potential diagnostic biomarkers of gastric cancer-associated malignant ascites
Presenter: Hye Sook Han
Session: Poster Display session 3
Resources:
Abstract
5574 - Results from TRIO030, a Pre-Surgical Tissue-Acquisition Study to Evaluate Molecular Alterations in Human Breast Cancer Tissue Following Short-Term Exposure to the Androgen Receptor Antagonist Darolutamide
Presenter: Hsiao-Wang Chen
Session: Poster Display session 3
Resources:
Abstract
1787 - JMJD2A is a novel epigenetic factor of chemotherapeutic susceptibility in gastric cancer
Presenter: Yasushi Sato
Session: Poster Display session 3
Resources:
Abstract
3140 - Phase 2 study of olaparib in previously treated advanced solid tumors with homologous recombination repair mutation (HRRm) or homologous recombination repair deficiency (HRD): LYNK-002
Presenter: David Hyman
Session: Poster Display session 3
Resources:
Abstract